BK virus nephropathy (BKVN) has emerged as an important
|
|
- Ralph Blake
- 5 years ago
- Views:
Transcription
1 BK Virus Nephropathy in Pediatric Renal Transplant Recipients: An Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry Jodi M. Smith,* Vikas R. Dharnidharka, Lynya Talley, Karen Martz, and Ruth A. McDonald* *Department of Pediatrics, Division of Nephrology, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington; Division of Pediatric Nephrology, University of Florida College of Medicine, Gainesville, Florida; and EMMES Corp., Rockville, Maryland Background and Objectives: There is limited information regarding BK virus nephropathy in pediatric kidney transplantation. The objective of this study was to evaluate cases of BK virus nephropathy in the North American Pediatric Renal Trials and Collaborative Studies database. Design, Setting, Participants, & Measurements: Using a questionnaire that was sent to North American Pediatric Renal Trials and Collaborative Studies centers, we assessed the incidence, risk factors, clinical features, and outcomes of BK virus nephropathy in pediatric renal transplant recipients who received a transplant between 2000 and Results: BK virus nephropathy was reported in 25 (4.6%) of 542 patients at a median onset of 10.1 mo after transplantation. The median age was 11 yr. All patients who were tested reported BK viruria, and 19 (91%) of 21 who had plasma tested reported BK viremia. Treatment of BK virus nephropathy included reduction of immunosuppression (84%), cidofovir (24%), leflunomide (8%), and intravenous Ig (20%). Simultaneous rejection treatment was reported in four (16%). The median creatinine was 2.0 mg/dl at a mean follow-up of 24 mo. There were six (24%) graft failures in the patients with BK virus nephropathy at a mean of 24 mo after diagnosis. Rejection occurred in eight (32%) after diagnosis. Multivariate analysis showed that use of polyclonal induction therapy and zero HLA DR mismatch were associated with the development of BK virus nephropathy. Conclusions: This first multicenter, retrospective, cohort study of BK virus nephropathy in pediatric renal transplant recipients found a BK virus nephropathy incidence of 4.6% and identified polyclonal induction and zero HLA DR mismatch as significant risk factors for BK virus nephropathy. Clin J Am Soc Nephrol 2: , doi: /CJN Received December 4, Accepted June 20, Published online ahead of print. Publication date available at Address correspondence to: Dr. Jodi M. Smith, Division of Nephrology, Children s Hospital and Regional Medical Center, University of Washington, 4800 Sand Point Way NE, M1 5, Seattle, WA Phone: ; Fax: ; jodi.smith@seattlechildrens.org BK virus nephropathy (BKVN) has emerged as an important cause of progressive graft dysfunction in renal transplantation, with incidence rates ranging from 1 to 10% (1 5). Numerous potential risk factors have been identified, including specific immunosuppressive agents (tacrolimus, mycophenolate mofetil), previous rejection, male gender, age, ethnicity, HLA mismatch, and BKV serostatus (1,4,6 9). Since the early reports in 1997, graft outcomes have significantly improved, likely as a result of increased awareness with early diagnosis and intervention. Despite numerous studies in adults, there are limited reports of BKV and BKVN in the pediatric renal transplant population, likely because of the small number of cases that a single pediatric center may encounter (2,9,10 14). We performed a retrospective questionnaire cohort study of multiple pediatric renal transplant centers using the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) transplant registry to describe the incidence, clinical features, risk factors, and outcomes of BKVN. Materials and Methods Study Population Since its inception in 1987, the scientific registry of NAPRTCS has enrolled 8000 patients who have received one or more renal transplants. Data collection methods have been previously reported (15). Briefly, the NAPRTCS has 150 participating medical centers in the United States, Canada, Mexico, and Costa Rica. The data on pediatric transplantation are derived from centers that collect information at the time of transplantation, 1 and 6 mo after transplantation, and every 6 mo thereafter. The initial transplant information consists of recipient age, gender, race, primary disease, type and duration of dialysis, type of transplant, degree of HLA mismatch, ischemia time, peak panel reactive antibody, induction therapy, height, and weight. At 30 d, data collected include graft outcome, initial immunosuppressive therapy, complications, and re-hospitalizations. Thereafter, information is collected every 6 mo regarding height, weight, serum creatinine, type and dosage of immunosuppressive therapy, and the use of other concomitant medications. Copyright 2007 by the American Society of Nephrology ISSN: /
2 1038 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 2: , 2007 For this study, a specific BKVN questionnaire was sent to 86 participating centers and included questions on diagnosis, clinical features, viral load, immunosuppression, treatment, and outcome. These centers were selected on the basis of whether they had contributed data in the years 2000 to 2004 (the period of the study). Definitions Cases of BKVN were defined by the center. The definition of BKVN was made by the centers on the basis of histologic diagnosis and the intention to treat as BKVN. We included cases that occurred in patients who received a transplant after January 1, 2000, to analyze patients who were on immunosuppressive medications of the current era. In addition, patients had to have at least 12 mo of follow-up to have adequate time to evaluate outcomes. Statistical Analyses Univariate analysis of risk factors was done using the two-tailed Fisher exact, 2,ort test, as appropriate. A multivariate logistic regression analysis was used to identify variables related to the development of BKVN. The full model included age, race, gender, transplant year, primary diagnosis, donor source, acute tubular necrosis, cold ischemia time, HLA-A, HLA-B, HLA-DR, initial immunosuppression (prednisone, cyclosporin A [CsA], tacrolimus, mycophenolate mofetil [MMF], and sirolimus), and induction antibody therapy. A backward selection procedure was used to select the most parsimonious model for BKVN development. Results Study Population Eight-six institutions and 1246 patients were eligible for the study and received questionnaires. Results were returned from 52 (60%) institutions and 542 patients. Table 1 shows the characteristics of the study population. Twenty-five (4.6%) patients were identified by their centers as having BKVN. The median onset of BKVN was 10.1 mo (range 1.8 to 38.3 mo) after transplantation. Diagnosis of BKVN At the time of diagnosis, 21 (100%) of 21 reported viruria (17 by PCR and four by decoy cells) and 19 (91%) of 21 reported viremia. There was histologic evidence of BKVN in 24 (96%) of 25 cases at the time of diagnosis. The mean creatinine at time of diagnosis was 1.8 mg/dl (SE 0.2). The baseline mean creatinine defined as stable creatinine before the diagnosis of BKVN was 1.1 mg/dl (SE 0.1). Treatment and Outcome of BKVN Twenty-one (84%) patients had a reduction of their immunosuppression. Specifically, 11 (53%) of 21 had their CsA/tacrolimus reduced or stopped, 18 (86%) of 21 had their MMF reduced or stopped, and five (24%) of 21 had their sirolimus reduced or stopped. Three patients had both their calcineurin inhibitor and sirolimus reduced or stopped. Cidofovir was used in six (24%) cases, leflunomide in 2 (8%), and intravenous Ig in five (20%). Four (16%) patients had simultaneous treatment of rejection. Of the 21 patients with BK viruria, 17 were retested and 10 cleared the viruria at a median of 6 mo (range 1 to 17 mo). Of the 19 patients with BK viremia, 13 had clearance at a median of 5 mo (range 0.5 to 14 mo). The median creatinine was 2.0 mg/dl (range 0.5 to 14.6) at a mean follow-up of 24 mo. Looking at rejection, BK cases have eight (32%) documented rejections. A time-to-first rejection (after development of BKVN) analysis indicates a 1-yr rejection rate of 25.1% ( 8.9) and a 2-yr rejection rate of 39.0% ( 11.5). There were six (24%) graft failures in the patients with BKVN at a mean of 24 mo after diagnosis. Two of these six graft failures were in the patients who had both their calcineurin inhibitor and sirolimus reduced or stopped. A time-to-event analysis estimates a graft survival rate (SE) of 87.8% ( 6.6) at 1 yr and 69.7% ( 10.8) at 2 yr after development of BKVN. Analysis of Risk Factors Table 1 shows the results of univariate analyses of potential risk factors for the development of BKVN. There was no significant difference in rates of BKVN when considering gender, ethnicity, age, transplant year, donor source, cause of primary disease, cold ischemia time, acute tubular necrosis, or type of maintenance immunosuppression. Induction with polyclonal antibody therapy was associated with BKVN (P ). Table 2 shows the univariate analysis of HLA A, B, and DR mismatch data where zero HLA-A (P ), zero HLA-B (P ), and zero HLA-DR mismatch (P ) were associated with BKVN. Table 3 shows the results of a multivariate logistic regression analysis. Variables in the model included age, gender, race, donor source, HLA, era of transplant, primary diagnosis, and immunosuppression (induction and maintenance). Use of polyclonal induction therapy (odds ratio [OR] 11.04; 95% confidence interval [CI] 2.94 to 41.52) and zero HLA-DR mismatch were significant predictors of BKVN (OR 7.31; 95% CI 2.58 to 20.71). Discussion BKVN has emerged as an important cause of graft dysfunction in renal transplantation. Analysis of the NAPRTCS registry found that the incidence of BKVN was 4.6% among recent pediatric renal transplant recipients, similar to adult data. Polyclonal induction antibody use and zero HLA mismatch were associated with a significantly higher risk for BKVN. Previously identified risk factors including age, gender, ethnicity, type of maintenance immunosuppression, and rejection history were not identified as risk factors in this analysis. The majority of patients were treated with reduction of immunosuppression alone, with graft survival of 76% and a median creatinine of 2.0 mg/dl at a mean follow-up of 24 mo. The intensity of immunosuppression has been identified as a risk factor for the development of BKVN. No specific maintenance immunosuppressive agent is exclusively associated with BKVN development, but patients who receive the combination of tacrolimus, MMF, and prednisone have been found to be at high risk (1,16). Our study did not identify a specific maintenance immunosuppressive medication to be associated with BKVN. We did observe an association between use of polyclonal induction therapy and BKVN (OR 11.04; 95% CI 2.94 to 41.52). Polyclonal induction therapy was recently associated with an increased risk for infectious complications in pediatric renal transplant patients (17). Other studies have reported that
3 Clin J Am Soc Nephrol 2: , 2007 BK Virus Nephropathy in Pediatrics 1039 Table 1. Univariate analysis of patient and donor characteristics a Characteristic BK No BK Total n % n % n % Exact 2 P b Total Gender male female Race white black Hispanic other Age (yr) 0 to to to Transplant year Donor source missing living donor deceased donor Primary diagnosis structural GN FSGS other Cold ischemia time live donor h h missing ATN (dialysis in first week) yes no missing Induction therapy none monoclonal polyclonal Primary immunosuppression CsA tacrolimus MMF azathioprine sirolimus prednisone a ATN, acute tubular necrosis; CsA, cyclosporin A; GN, glomerulonephritis; MMF, mycophenolate mofetil. b Because of small sample sizes, exact P values are presented.
4 1040 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 2: , 2007 Table 2. Univariate analysis of HLA mismatches and BKVN a Parameter BK No BKVN Total n % n % n % 2 P b Total HLA-A HLA-B HLA-DR a BKVN, BK virus nephropathy. b Because of small sample sizes, exact P values are presented. Table 3. Multivariate logistic analysis of risk factors for BKVN a Factor Comparison Group Reference Group OR 95% CI P HLA-DR 0 mismatches 2 mismatches to overall P mismatches to Induction therapy Monoclonal None to overall P Polyclonal to a CI, confidence interval; OR, odds ratio. use of antilymphocyte agents for the treatment of steroid-resistant rejection is associated with BKV replication in patients who are on tacrolimus or MMF maintenance therapy (7,18,19). However, other studies that examined BKV specifically did not find an association between use of antilymphocyte preparations and risk for BK viruria, viremia, or BKVN (7,16,18,20). HLA mismatching has been identified as a risk factor for BKVN in both retrospective and prospective studies among adult renal transplant patients (7,19). The increased rejection risk with HLA mismatching (21,22) through its treatment with escalation of immunosuppression and/or via direct rejectionrelated inflammatory responses has been proposed as a potential mechanism for this association. Other studies have not identified HLA mismatching as a risk factor (4,16,23). Limited data exist on the role of HLA as a risk factor in pediatrics. In our study, we found that zero HLA-DR mismatch was associated with a 7.3-fold higher risk for BKVN. There are several potential explanations for this finding. Those with zero mismatch may represent younger donors who are BKV seronegative, a previously identified risk factor. We were not able to evaluate BKV serostatus because this test was not routinely performed at centers. Recipient age was not a significant risk factor in the univariate or multivariate analyses. Higher levels of immunosuppression would have placed those with zero HLA-DR mismatch at increased risk for BKVN. We did find that more patients with BKVN had received polyclonal induction therapy, which one could postulate may represent overimmunosuppression of a relatively low-risk group. In terms of maintenance immunosuppression, we found no difference in the levels of CsA, tacrolimus, or sirolimus. NAPRTCS does not routinely collect data on mycophenolic acid levels. In addition, there was no difference in the number of rejection episodes. Finally, there is evidence for increased risk for viral complications in the setting of well-hla-matched transplants. A dualistic effect of HLA has been proposed with HLA compatibility reducing rejection risk but also potentially augmenting MHCrestricted cellular immune mechanisms of injury (24). In liver transplantation, HLA matching has been associated with cytomegalovirus hepatitis and the development of chronic rejection thought to be precipitated by cytomegalovirus-induced HLA antigen expression in susceptible patients (24 26). On the basis of the evidence that BK viremia and viruria do appear before the onset of histologic BKVN, prospective screening for BKV is recommended as part of routine posttransplantation follow-up (27). Screening was performed in the majority of NAPRTCS centers with 21 (84%) of 25 centers using urine either by cytology or by PCR and 21 (84%) of 25 testing blood by PCR.
5 Clin J Am Soc Nephrol 2: , 2007 BK Virus Nephropathy in Pediatrics 1041 Reduction of immunosuppression is the primary mode of intervention for the treatment of BKVN (3,27,28). This approach was successful in the majority (84%) of patients in this study. Biopsy-proven rejection after immunosuppression reduction is reported in up to 25% of patients (29), which compares to 32% seen in the NAPRTCS cohort. Although there have been no controlled trials, antiviral therapy with cidofovir has been reported in cases in which immunosuppression reduction is not sufficient (13,14,30). In our study, cidofovir was used in six (24%) of 25 cases. Rates of graft loss have improved with the increased awareness and introduction of routine viral screening. More recent studies report graft loss rates between 10 and 50%. In the NAPRTCS cohort, there was a 76% graft survival at 24 mo after diagnosis. We acknowledge the limitations of our study. The NAPRTCS database is a voluntary database; therefore, a sampling bias may be present. The retrospective nature of the study with questionnaires as the data collection method introduces the possibility of recall bias and a general underestimation of the true incidence of BKVN. However, given the restriction to cases from 2000 to 2004 and that each pediatric center typically encounters only one to two cases, we hope that this underestimation is minimal. The definition of BKVN was made by the centers themselves on the basis of histologic diagnosis and the intention to treat as BKVN. We did not define specific histologic diagnostic criteria. As such, there is a risk for misclassification of noncases as cases, and this could have an impact on the results. We do not have information on the viral surveillance strategies of the participating centers, which may have had an impact on the severity of disease at diagnosis. In addition, treatment approaches differed, which limits the interpretability of the outcome data. Conclusions This first multicenter, retrospective, cohort study of BKVN in pediatric renal transplant recipients found a BKVN incidence of 4.6% and graft survival of 76%, which are similar to adult reports. Polyclonal induction therapy use and zero HLA mismatch were identified as significant risk factors for BKVN. Further studies to confirm these findings are warranted. Acknowledgments The North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) is supported by unrestricted educational grants from Novartis, AMGEN, and Genentech. This study was presented in part at the annual meeting of the American Society of Nephrology, November 8 through 13, 2005; Philadelphia, PA. Disclosures None. References 1. Mengel M, Marwedel M, Radermacher J, Eden G, Schwarz A, Haller H, Kreipe H: Incidence of polyomavirus-nephropathy in renal allografts: Influence of modern immunosuppressive drugs. Nephrol Dial Transplant 18: , Ginevri F, De Santis R, Comoli P, Pastorino N, Rossi C, Botti G, Fontana I, Nocera A, Cardillo M, Ciardi MR, Locatelli F, Maccario R, Perfumo F, Azzi A: Polyomavirus BK infection in pediatric kidney-allograft recipients: A single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 75: , Hirsch HH, Steiger J: Polyomavirus BK. Lancet Infect Dis 3: , Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR: Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 13: , Buehrig CK, Lager DJ, Stegall MD, Kreps MA, Kremers WK, Gloor JM, Schwab TR, Velosa JA, Fidler ME, Larson TS, Griffin MD: Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 64: , Nickeleit V, Klimkait T, Binet IF, Dalquen P, Del Zenero V, Thiel G, Mihatsch MJ, Hirsch HH: Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 342: , Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J: Prospective study of polyomavirus type BK replication and nephropathy in renaltransplant recipients. N Engl J Med 347: , Mathur VS, Olson JL, Darragh TM, Yen TS: Polyomavirusinduced interstitial nephritis in two renal transplant recipients: Case reports and review of the literature. Am J Kidney Dis 29: , Smith JM, McDonald RA, Finn LS, Healey PJ, Davis CL, Limaye AP: Polyoma virus nephropathy in pediatric kidney transplant recipients. Am J Transplant 4: , Muller A, Beck B, Theilemann K, Stapenhorst L, Licht C, Michalk D, Franzen C, Hoppe B: Detection of polyomavirus BK and JC in children with kidney diseases and renal transplant recipients. Pediatr Infect Dis J 24: , Hymes LC, Warshaw BL: Polyomavirus (BK) in pediatric renal transplants: Evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant 10: , Alexander RT, Langlois V, Tellier R, Robinson L, Hebert D: The prevalence of BK viremia and urinary viral shedding in a pediatric renal transplant population: A single-center retrospective analysis. Pediatr Transplant 10: , Vats A, Shapiro R, Singh Randhawa P, Scantlebury V, Tuzuner A, Saxena M, Moritz ML, Beattie TJ, Gonwa T, Green MD, Ellis D: Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 75: , Araya CE, Lew JF, Fennell RS 3rd, Neiberger RE, Dharnidharka VR: Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy. Pediatr Transplant 10: 32 37, McEnery P, Arbus G, Stablein DM, Tejani A: Renal transplantation in children: A report of the North American
6 1042 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 2: , 2007 Pediatric Renal Transplant Cooperative Study (NAPRTCS). N Engl J Med 326: , Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA: Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 5: , Puliyanda DP, Stablein DM, Dharnidharka VR: Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: A NAPRTCS report. Am J Transplant 7: , Binet I, Nickeleit V, Hirsch HH, Prince O, Dalquen P, Gudat F, Mihatsch MJ, Thiel G: Polyomavirus disease under new immunosuppressive drugs: A cause of renal graft dysfunction and graft loss. Transplantation 67: , Awadalla Y, Randhawa P, Ruppert K, Zeevi A, Duquesnoy RJ: HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant 4: , Wong W, Pascual M, Hirsch HH, Goggins W, Bae J, Farrell ML, Delmonico FL, Cosimi AB, Tolkoff-Rubin N: BK virus replication in kidney transplant recipients who received thymoglobulin induction. J Am Soc Nephrol 14: SU-PO539, Cecka JM: The role of HLA in renal transplantation. Hum Immunol 56: 6 16, Opelz G: Impact of HLA compatibility on survival of kidney transplants from unrelated live donors. Transplantation 64: , Bohl DL, Storch GA, Ryschkewitsch C, Gaudreault-Keener M, Schnitzler MA, Major EO, Brennan DC: Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 5: , Donaldson P, Underhill J, Doherty D, Hayllar K, Calne R, Tan KC, O Grady J, Wight D, Portmann B, Williams R: Influence of human leukocyte antigen matching on liver allograft survival and rejection: The dualistic effect. Hepatology 17: , O Grady JG, Alexander GJ, Sutherland S, Donaldson PT, Harvey F, Portmann B, Calne RY, Williams R: Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent co-factors in pathogenesis of vanishing bileduct syndrome after liver transplantation. Lancet 2: , Manez R, White LT, Linden P, Kusne S, Martin M, Kramer D, Demetris AJ, Van Thiel DH, Starzl TE, Duquesnoy RJ: The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation 55: , Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, Mihatsch MJ, Nickeleit V, Ramos E, Randhawa P, Shapiro R, Steiger J, Suthanthiran M, Trofe J: Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 79: , Randhawa PS, Demetris AJ: Nephropathy due to polyomavirus type BK. N Engl J Med 342: , Randhawa PS, Finkelstein S, Scantlebury V, Shapiro R, Vivas C, Jordan M, Picken MM, Demetris AJ: Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 67: , Kadambi PV, Josephson MA, Williams J, Corey L, Jerome KR, Meehan SM, Limaye AP: Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 3: , 2003
BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationThe New England Journal of Medicine PROSPECTIVE STUDY OF POLYOMAVIRUS TYPE BK REPLICATION AND NEPHROPATHY IN RENAL-TRANSPLANT RECIPIENTS
PROSPECTIVE STUDY OF POLYOMAVUS TYPE BK REPLICATION AND NEPHROPATHY IN RENAL-TRANSPLANT RECIPIENTS HANS H. HSCH, M.D., WENDY KNOWLES, PH.D., MICHAEL DICKENMANN, M.D., JAKOB PASSWEG, M.D., THOMAS KLIMKAIT,
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationIntravenous immunoglobulin in BK virus nephropathy
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Intravenous immunoglobulin in BK virus nephropathy Elizabeth I. Anyaegbu Driscoll Children's Hospital Stanley
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationHistological Patterns of Polyomavirus Nephropathy: Correlation with Graft Outcome and Viral Load
American Journal of Transplantation 2004; 4: 2082 2092 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2004 doi: 10.1111/j.1600-6143.2004.00603.x Histological Patterns of Polyomavirus Nephropathy:
More informationRisk factors in the progression of BK virus-associated nephropathy in renal transplant recipients
ORIGINAL ARTICLE Korean J Intern Med 15;3:865-872 http://dx.doi.org/1.394/kjim.15.3.6.865 Risk factors in the progression of BK virus-associated nephropathy in renal transplant recipients Hae Min Lee 1,*,
More informationQuantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN
NEW MICROBIOLOGICA, 34, 165-171, 2011 Quantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN Caterina Patrizia Pollara 1, Silvia Corbellini
More information1266 TRANSPLANTATION. Vol. 75, No. 8
1266 TRANSPLANTATION codynamic studies of one or two doses of daclizumab in renal transplant patients. Am J Transplant 2001; 1: 385 (A 991). 12. Niemeyer G, Koch M, Light S, et al. Long-term safety, tolerability
More informationBK virus nephritis after renal transplantation
http://www.kidney-international.org & 2006 International Society of Nephrology review BK virus nephritis after renal transplantation S Hariharan 1 1 Division of Nephrology, Medical College of Wisconsin,
More informationThe term BK originated from a patient s initials, in
BK Virus Nephritis after Renal Transplantation Aaron Dall and Sundaram Hariharan Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin BK virus nephritis is an increasing problem and
More informationTransient versus Persistent BK Viremia and Long-Term Outcomes after Kidney and Kidney Pancreas Transplantation
Article Transient versus Persistent and Long-Term Outcomes after Kidney and Kidney Pancreas Transplantation Nissreen Elfadawy,* Stuart M. Flechner,* Jesse D. Schold, Titte R. Srinivas, Emilio Poggio,*
More informationPediatric Kidney Transplantation
Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationLongitudinal Analysis of Levels of Immunoglobulins against BK Virus Capsid Proteins in Kidney Transplant Recipients
CLINICAL AND VACCINE IMMUNOLOGY, Oct. 2008, p. 1564 1571 Vol. 15, No. 10 1556-6811/08/$08.00 0 doi:10.1128/cvi.00206-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Longitudinal
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationSince the 1990s, renal transplantation has become the treatment
Polyomavirus in Renal Transplantation: A Hot Problem Catherine Bonvoisin, Laurent Weekers, Patricia Xhignesse, Stéphanie Grosch, Miroslav Milicevic, and Jean-Marie Krzesinski Polyomavirus BK has emerged
More informationPREVENTION AND TREATMENT OF BKV NEPHROPATHY Petra Reinke, Berlin, Germany. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy
PREVENTION AND TREATMENT OF BKV NEPHROPATHY Petra Reinke, Berlin, Germany Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Petra Reinke Department of Nephrology University Hospital
More informationBK virus, kidney transplant, polycystic kidney disease. 1-3 Following mild or asymptomatic primary infection, typically early
Received: 22 June 2018 Revised: 17 July 2018 Accepted: 6 August 2018 DOI: 10.1111/tid.12974 ORIGINAL ARTICLE Kidney transplant recipients with polycystic kidney disease have a lower risk of post- transplant
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationTrends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant and relationship to BK virus infection
2565 Nephrol Dial Transplant (2012) 27: 2565 2570 doi: 10.1093/ndt/gfr675 Advance Access publication 13 December 2011 Trends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant
More informationAdjuvant Role of p53 Immunostaining in Detecting BK Viral Infection in Renal Allograft Biopsies
Available online at www.annclinlabsci.org 324 Annals of Clinical & Laboratory Science, vol. 40, no. 4, 2010 Adjuvant Role of p53 Immunostaining in Detecting BK Viral Infection in Renal Allograft Biopsies
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 28 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 27 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationClinical Grand Rounds. May 2016
Clinical Grand Rounds May 2016 The Case 51M African American w/ HTN, ESRD (on HD for 13 years) who underwent a DDRTx in June 2015. Complications: BK viremia with AKI in Jan 2016---MMF held and tacro dose
More informationNorth American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. Renal Transplantation. Chronic Renal Insufficiency
North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2006 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationHHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2015 September 01.
Kidney transplant results in children: progress made, but blacks lag behind Vikas R. Dharnidharka, MD, MPH 1 and Michael E. Seifert, MD 1,2 1 Division of Pediatric Nephrology, Washington University School
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationOriginal article Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature
Antiviral Therapy 3:00 009 Original article Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature Frédéric Lamoth,2 *, Manuel Pascual
More informationClinicalValidation Study of Quantitative Real-Time PCR Assay for Detection and Monitoring of BK Virus Nephropathy
Available online at www.annclinlabsci.org ClinicalValidation Study of Quantitative Real-Time PCR Assay for Detection and Monitoring of BK Virus Nephropathy 455 Satoru Kudose 1 and Jianli Dong 2 Departments
More informationArticle. Leflunomide Efficacy and Pharmacodynamics for the Treatment of BK Viral Infection
Article Leflunomide Efficacy and Pharmacodynamics for the Treatment of BK Viral Infection Jill C. Krisl,* David J. Taber,* Nicole Pilch,* Kenneth Chavin, Charles Bratton, Beje Thomas, John McGillicuddy,
More informationRon Shapiro, MD, Abdul S. Rao, MD, D. Phil., Paulo Fontes, MD, Adrianna Zeevi, Ph.D., Mark Jordan, MD, Velma P. Scantlebury, MD,
Kidney IBone Marrow Transplantation Ron Shapiro, MD, Abdul S. Rao, MD, D. Phil., Paulo Fontes, MD, Adrianna Zeevi, Ph.D., Mark Jordan, MD, Velma P. Scantlebury, MD, Carlos Vivas, MD, H. Albin Gritsch,
More informationPresence of Urinary Haufen Accurately Predicts Polyomavirus Nephropathy
JASN Express. Published on January 21, 2009 as doi: 10.1681/ASN.2008010117 www.jasn.org Presence of Urinary Haufen Accurately Predicts Polyomavirus Nephropathy Harsharan K. Singh,* Kenneth A. Andreoni,
More informationAs immunosuppression for kidney transplantation
NARRATIVE REVIEW Polyomavirus Nephropathy: A Current Perspective and Clinical Considerations Alexander C. Wiseman, MD During the last decade, the human polyomaviruses (BK virus and, much less commonly,
More informationKidney Allograft Fibrosis and Atrophy Early After Living Donor Transplantation
American Journal of Transplantation 2005; 5: 1130 1136 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2005 doi: 10.1111/j.1600-6143.2005.00811.x Kidney Allograft Fibrosis and Atrophy Early After
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.625, ISSN: , Volume 3, Issue 1, February 2015
DETECTION OF BK POLYOMAVIRUS USING REAL TIME PCR AND URINE CYTOLOGY IN 99 RENAL TRANSPLANT RECIPIENTS ASMAA B. AL-OBAIDI 1 KAIS H. ABD 2 MANAL A HABIB 3 HAIDER S. KADHIM 1 HAIDAR A.SHAMRAN 4 1 Microbiology
More informationOrgan rejection is one of the serious
Original Article Outcomes of Late Corticosteroid Withdrawal after Renal Transplantation in Patients Exposed to Tacrolimus and/or Mycophenolate Mofetil: Meta-Analysis of Randomized Controlled Trials A.
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationCases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center
Cases: CMV, HCV, BKV and Kidney Transplantation Simin Goral, MD University of Pennsylvania Medical Center Disclosures Grant support: Otsuka Pharmaceuticals, Astellas Pharma, Angion, AstraZeneca, and Kadmon
More informationClinical significance of quantitative and qualitative detection of BK and JC virus in blood and urine of renal transplantation recipients
Open Access Original Article Clinical significance of quantitative and qualitative detection of BK and JC virus in blood and urine of renal transplantation recipients Liangwei Qiao 1, Qingshan Qu 2, Xin
More informationDecoy Cell Viruria in Kidney Transplant Patients. Does it correlate with Renal Function?
Decoy Cell Viruria in Kidney Transplant Patients. Does it correlate with Renal Function? Akram Abedi (1) Mojgan Mortazavi (2) Omid Mirmosayyeb (3,4) Shahram Taheri (2) Nooshin Afsharmoghadam (1) Majid
More informationClinical Study Over Ten-Year Kidney Graft Survival Determinants
International Nephrology Volume 2012, Article ID 302974, 5 pages doi:10.1155/2012/302974 Clinical Study Over Ten-Year Kidney Graft Survival Determinants Anabela Malho Guedes, 1, 2 Jorge Malheiro, 1 Isabel
More informationABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies
Nephrol Dial Transplant (2009) 24: 298 303 doi: 10.1093/ndt/gfn478 Advance Access publication 26 August 2008 Original Article ABO blood group-incompatible living donor kidney transplantation: a prospective,
More informationBK Viral Infection and Malignancy in Renal Transplantation ~A Case History~
BK Viral Infection and Malignancy in Renal Transplantation ~A Case History~ Mariko Toyoda, MD Department of Nephrology, Japanese Red Cross Kumamoto Hospital Statement of Disclosure The author does not
More informationInt J Clin Exp Med 2015;8(9): /ISSN: /IJCEM
Int J Clin Exp Med 2015;8(9):16340-16345 www.ijcem.com /ISSN:1940-5901/IJCEM0011301 Original Article Comparison of anti-reflux mechanism between Double-J-Stent and standart Double-J-Stent use for risk
More informationAcute rejection and late renal transplant failure: Risk factors and prognosis
Nephrol Dial Transplant (2004) 19 [Suppl 3]: iii38 iii42 DOI: 10.1093/ndt/gfh1013 Acute rejection and late renal transplant failure: Risk factors and prognosis Luis M. Pallardo Mateu 1, Asuncio n Sancho
More informationRecognition and Treatment of Chronic Allograft Dysfunction
Recognition and Treatment of Chronic Allograft Dysfunction Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs
More informationImpact of Subclinical Rejection on Transplantation
Trends in Transplantation 2007;1:56-60 Impact of Subclinical Rejection on Transplantation David N. Rush for the Winnipeg Transplant Group Transplant Manitoba Adult Kidney Program, University of Manitoba,
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationNephrology Grand Rounds
Nephrology Grand Rounds PTLD in Kidney Transplantation Charles Le University of Colorado 6/15/12 Objectives Background Pathogenesis Epidemiology and Clinical Manifestation Incidence Risk Factors CNS Lymphoma
More informationJournal of Global Pharma Technology
Journal of Global Pharma Technology Available Online at www.jgpt.co.in ISSN: 0975-8542 RESEARCH ARTICLE The Possible Role of JC Polyomavirus after Kidney Transplantation Asmaa B Al-Obaidi 1, Haidar A Shamran
More informationPrevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients
TRANSPLANTATION Prevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients Mohsen Nafar, 1 Azamolsadat Roshan, 2 Fatemeh Pour-Reza-Gholi, 1 Fariba Samadian, 1 Pedram
More informationTESTING FOR POLYOMAVIRUS BK DNA TO IDENTIFY RENAL-ALLOGRAFT RECIPIENTS WITH VIRAL NEPHROPATHY
TESTING FOR POLYOMAVIRUS TYPE BK DNA IN PLASMA TO IDENTIFY RENAL-ALLOGRAFT RECIPIENTS WITH VIRAL NEPHROPATHY VOLKER NICKELEIT, M.D., THOMAS KLIMKAIT, PH.D., ISABELLE F. BINET, M.D., PETER DALQUEN, M.D.,
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationPersistent BK Viremia Does Not Increase Intermediate- Term Graft Loss but Is Associated with De Novo Donor-Specific Antibodies
CLINICAL RESEARCH www.jasn.org Persistent BK Viremia Does Not Increase Intermediate- Term Graft Loss but Is Associated with De Novo Donor-Specific Antibodies Deirdre Sawinski,* Kimberly A. Forde, Jennifer
More informationORIGINAL ARTICLE. Received April 30, 2007; accepted June
LIVER TRANSPLANTATION 13:1405-1413, 2007 ORIGINAL ARTICLE Human Leukocyte Antigen and Adult Living- Donor Liver Transplantation Outcomes: An Analysis of the Organ Procurement and Transplantation Network
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationBK Virus: Opportunity Makes a Pathogen
IMMUNOCOMPROMISED HOSTS David R. Snydman, Section Editor INVITED ARTICLE BK Virus: Opportunity Makes a Pathogen Hans H. Hirsch Transplantation Virology, Department of Clinical Biological Sciences, University
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationThe Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database
LIVER TRANSPLANTATION 12:652-658, 2006 ORIGINAL ARTICLE The Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database Victor Navarro,
More informationBK Virus in Kidney Transplant: Current Concepts, Recent Advances, and Future Directions
RevIew BK Virus in Kidney Transplant: Current Concepts, Recent Advances, and Future Directions Rajeev Sharma, 1 Stephanie Tzetzo, 2 Sunil Patel, 1 Mareena Zachariah, 3 Sonakshi Sharma, 4 Thomas Melendy
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationHow do the KDIGO Clinical Practice Guidelines on the Care of Kidney Transplant Recipients apply to the UK?
How do the KDIGO Clinical Practice Guidelines on the Care of Kidney Transplant Recipients apply to the UK? Dr Richard Baker & Professor Alan Jardine, co-authors, forthcoming Renal Association module on
More informationRejection after simultaneous pancreas kidney transplantation
Nephrol Dial Transplant (2005) 20 [Suppl 2]: ii11 ii17 doi:10.1093/ndt/gfh1077 Rejection after simultaneous pancreas kidney transplantation Helmut Arbogast 1, Jacques Malaise 3, Wolf-Dieter Illner 1, Anwar
More informationReduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival
Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function
More informationChronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.
Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationPancreas after Kidney Transplants in Posturemic Patients with Type I Diabetes Mellitus
J Am Soc Nephrol 12: 2490 2499, 2001 Pancreas after Kidney Transplants in Posturemic Patients with Type I Diabetes Mellitus ANGELIKA C. GRUESSNER, DAVID E. R. SUTHERLAND, DAVID L. DUNN, JOHN S. NAJARIAN,
More informationRyszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation
Trends in Transplant. 2011;5:115-20 Ryszard Grenda: Steroid-Free Pediatric Transplantation Early Steroid Withdrawal in Pediatric Renal Transplantation Ryszard Grenda Department of Nephrology, Kidney Transplantation
More informationLack of Significant Co-Activation of BKV and CMV in Renal Transplant Patients: An Institutional Experience
Volume 1, Issue 1, pp: 1-6 Research Article Introduction Open Access Lack of Significant Co-Activation of BKV and CMV in Renal Transplant Patients: An Institutional Experience Minh-Thu Nguyen, BS 1, Phylicia
More informationSimultaneous pancreas/kidney transplant recipients present with late-onset BK polyomavirus-associated nephropathy
16. Paoletti E, Marsano L, Bellino D et al. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients; a 1 year, randomized, controlled trial. Transplantation 2012; 93:
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationTopic BKV Polyoma Virus
Topic 13.1. BKV Polyoma Virus Author: Helen Pilmore and Paul Manley GUIDELINES a. We suggest screening high risk kidney transplant recipients for BK polyoma virus (BKV) with quantitative plasma NAT. The
More informationTransplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes
Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes INTRODUCTION In patients awaiting a transplant, having antibodies reactive to HLA antigens present
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationJames E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant
James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 2, by the Massachusetts Medical Society VOLUME 342 M ARCH 2, 2 NUMBER 9 IMPROVED GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION IN THE UNITED STATES, 1988 TO
More informationCOMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS
COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS A COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS KEVIN C. MANGE, M.D.,
More informationGouvêa et al. Journal of Medical Case Reports (2017) 11:146 DOI /s
Gouvêa et al. Journal of Medical Case Reports (2017) 11:146 DOI 10.1186/s13256-017-1300-9 CASE REPORT Open Access BK polyomavirus nephropathy in two kidney transplant patients with distinct diagnostic
More informationOptimal use of plasma and urine BK viral loads for screening and predicting BK nephropathy
Boan et al. BMC Infectious Diseases (2016) 16:342 DOI 10.1186/s12879-016-1652-6 RESEARCH ARTICLE Open Access Optimal use of plasma and urine BK viral loads for screening and predicting BK nephropathy Peter
More informationLe migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE
Le migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE Best Therapy for Kidney Re- Transplantation? PREVENTION!!!! Registries CTS OPTN UNOS USRDS SRTR
More informationArticle. Simultaneous Pancreas Kidney Transplant versus Other Kidney Transplant Options in Patients with Type 2 Diabetes
Article Simultaneous Pancreas Kidney Transplant versus Other Kidney Transplant Options in Patients with Type 2 Diabetes Alexander C. Wiseman* and Jane Gralla Summary Background and objectives Current organ
More informationDesensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
More informationThe Renal Transplant Patient Updates for the Pediatrician Margret Bock, MD, MS * Jens Goebel, MD
Curr Treat Options Peds (2016) 2:112 119 DOI 10.1007/s40746-016-0049-5 Pediatric Nephrology (P Brophy, Section Editor) The Renal Transplant Patient Updates for the Pediatrician Margret Bock, MD, MS * Jens
More informationEffect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study
NDT Plus (2010) 3 [Suppl 2]: ii32 ii36 doi: 10.1093/ndtplus/sfq064 Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study Miguel Gonzalez-Molina 1, Miguel Angel
More informationImmunomodulator y effects of CMV disease
Immunomodulator y effects of CMV disease Oriol Manuel MD Service of Infectious Diseases and Transplantation Center University Hospital of Lausanne Switzerland Outline The transplant troll The indirect
More informationHealth technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:
An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status
More informationSignificance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis
Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Hatem Ali 1,2, Atif Mohiuddin 2,3, Ajay Sharma 2,3, Mohsen El Kosi 2,4 and Ahmed Halawa
More informationCalcineurin inhibitors in HLA-identical living related donor kidney transplantation
Nephrol Dial Transplant (2014) 29: 209 218 doi: 10.1093/ndt/gft447 Calcineurin inhibitors in HLA-identical living related donor kidney transplantation ABSTRACT Priya S. Verghese 1, Ty B. Dunn 2, Srinath
More informationIncidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review
Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Jessica Ludolph 1 Lynsey Biondi, MD 1,2 and Michael Moritz, MD 1,2 1 Department of Surgery,
More informationAdvances in immunosuppression have led to marked
Impact of Acute Rejection and New-Onset Diabetes on Long-Term Transplant Graft and Patient Survival Edward H. Cole,* Olwyn Johnston, Caren L. Rose, and John S. Gill *Division of Nephrology and Multiorgan
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More information